Linaclotide and Plecanatide: Guanylate Cyclase-C Agonists for Constipation
Both linaclotide and plecanatide are FDA-approved guanylate cyclase-C agonists that effectively treat chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) by increasing intestinal fluid secretion, with strong evidence supporting their use when over-the-counter agents fail 1.
Mechanism of Action
Both medications work identically at the molecular level:
- Activate guanylate cyclase-C receptors on the luminal surface of intestinal epithelial cells
- Increase cyclic guanosine monophosphate (cGMP) concentrations
- Stimulate chloride and bicarbonate secretion into the intestinal lumen
- Increase intestinal fluid and accelerate gastrointestinal transit
- Minimal systemic absorption, limiting systemic side effects 1
The key difference: plecanatide is pH-dependent, which theoretically limits diarrhea risk, though real-world data show similar diarrhea rates between the two agents 2, 3.
FDA-Approved Indications
Linaclotide 4:
- IBS-C in adults: 290 mcg daily
- CIC in adults: 145 mcg daily (or 72 mcg for better tolerability)
- Functional constipation in children 6-17 years: 72 mcg daily
Plecanatide 1:
- Both IBS-C and CIC in adults: 3 mg daily (same dose for both conditions)
- Not approved for pediatric use
Dosing and Administration
Linaclotide 4:
- Take on empty stomach, at least 30 minutes before first meal of the day
- Can be opened and mixed with applesauce or water if unable to swallow capsule whole
- Can be administered via nasogastric or gastrostomy tube
- Do not crush or chew capsules
Plecanatide 1:
- Can be taken with or without food (major practical advantage over linaclotide)
- Swallow whole
Clinical Efficacy
Linaclotide 1:
- Increases complete spontaneous bowel movements (CSBMs) by 1.37 per week (95% CI 1.07-1.95)
- Increases spontaneous bowel movements (SBMs) by 1.97 per week (95% CI 1.59-2.36)
- Improves stool consistency significantly (MD 1.25,95% CI 1.1-1.39)
- Increases responder rates 3-fold compared to placebo (RR 3.14,95% CI 1.68-5.88)
- Reduces abdominal pain, bloating, and discomfort in IBS-C trials, making it particularly useful when these symptoms coexist 1
- High certainty evidence for bowel movement outcomes
Plecanatide 1:
- Increases CSBMs by 1.1 per week (95% CI 0.85-1.35)
- Increases SBMs by 1.66 per week (95% CI 1.37-1.94)
- Improves stool consistency (MD 0.83,95% CI 0.6-1.05)
- Increases responder rates 78% compared to placebo (RR 1.78,95% CI 1.46-2.18)
- May reduce abdominal pain based on indirect evidence from IBS-C trials
- Moderate to high certainty evidence
Meta-analysis shows no statistically significant differences in efficacy between the two drugs 2, though linaclotide shows numerically higher improvements in bowel movements.
Adverse Effects and Safety
Diarrhea (Primary Concern for Both):
Linaclotide 1:
- 3.35 times more likely to cause diarrhea leading to discontinuation vs placebo (RR 3.35,95% CI 2.09-5.36)
- Absolute discontinuation rate: 4.7% in clinical trials
- 83 more cases per 1,000 patients (95% CI 38-154 more)
Plecanatide 1:
- 5.39 times more likely to cause diarrhea leading to discontinuation vs placebo (RR 5.39,95% CI 2.40-12.11)
- Absolute risk appears small: 27 more cases per 1,000 patients (95% CI 9-69 more)
Important caveat: FDA documentation reveals that different definitions of diarrhea were used in linaclotide vs plecanatide trials, making direct comparisons problematic 2. Meta-regression found no statistically significant differences in diarrhea rates when accounting for these methodological differences 2.
Other Adverse Effects:
- Lubiprostone (a different secretagogue) uniquely causes dyspnea and chest pain, which linaclotide and plecanatide do not 5
- Abdominal pain, bloating, and nausea occur but are less common than diarrhea 5
- Serious adverse events are rare for both medications 1
- No significant differences in outcomes for patients >65 years, though sample sizes were limited 1
Critical Safety Warning:
Linaclotide is CONTRAINDICATED in children <2 years of age due to risk of fatal dehydration demonstrated in neonatal mice 4. Also contraindicated in known or suspected mechanical GI obstruction 1.
Clinical Decision-Making Algorithm
When OTC laxatives fail in CIC or IBS-C:
If abdominal pain, bloating, or discomfort are prominent symptoms: Choose linaclotide (particularly the 290 mcg dose approved for IBS-C), as it has demonstrated superior effects on these symptoms 1
If patient cannot take medication on empty stomach or has compliance concerns: Choose plecanatide 3 mg, as it can be taken with or without food 1
If patient is highly concerned about diarrhea: Start with linaclotide 72 mcg or 145 mcg (lower doses for CIC) rather than the 290 mcg IBS-C dose, as diarrhea is dose-dependent 1
If initial therapy causes intolerable diarrhea: Reduce dose (linaclotide 145→72 mcg) or switch between agents, as individual response varies 1
For pediatric functional constipation (ages 6-17): Use linaclotide 72 mcg only, as plecanatide lacks pediatric approval 4
Duration of Treatment
- Clinical trials lasted 12 weeks for both medications 1
- FDA labels do not specify treatment duration limits 1
- Can be used long-term as replacement or adjunct to OTC agents
- Most common reasons for discontinuation: Loss of efficacy and insurance barriers, NOT adverse events 1
Common Pitfalls to Avoid
Don't prescribe linaclotide without emphasizing the empty stomach requirement (30 minutes before first meal) - this significantly impacts efficacy 1, 4
Don't assume plecanatide has less diarrhea risk based on its pH-dependent mechanism - real-world evidence shows similar rates 2
Don't overlook the abdominal pain benefits - if pain/bloating are prominent, linaclotide may provide dual benefits beyond just treating constipation 1
Don't prescribe linaclotide to children <6 years or any child <2 years (contraindicated due to dehydration risk) 4
Don't stop therapy prematurely for mild diarrhea - consider dose reduction first, as only 4.7% discontinued in trials 1
Don't forget to check for mechanical obstruction before prescribing linaclotide 1
Guideline Recommendations
The 2023 AGA-ACG Clinical Practice Guideline strongly recommends both medications when OTC agents fail 1:
- Linaclotide: Moderate overall certainty of evidence
- Plecanatide: Strong recommendation, moderate certainty of evidence
Both can be used as replacement or adjunct therapy to OTC agents, with the choice depending on symptom profile, dosing convenience, and individual tolerability 1.